Hollywood Star Sparks Cancer Treatment Frenzy

Two scientists conducting an experiment in a laboratory, one looking through a microscope and the other holding a flask with blue liquid

A quiet revolt is brewing in oncology clinics as desperate cancer patients turn to farm dewormers and ivermectin after a Hollywood star’s story went viral on Joe Rogan’s podcast.

Story Snapshot

Prescriptions for ivermectin and similar antiparasitic drugs surged among cancer patients after Mel Gibson’s appearance on Joe Rogan’s show.
Lab and animal studies suggest ivermectin can kill cancer cells, but doctors say there is still no proven benefit for humans.
Federal cancer researchers are now running formal trials, even as medical gatekeepers warn against off-label use.
Conservatives see a familiar pattern of censorship, distrust in institutions, and patients demanding more control over their care.

How a Podcast Clip Pushed Ivermectin Back Into the Cancer Fight

Mel Gibson’s January 2025 appearance on “The Joe Rogan Experience” lit a fuse when he described three friends with stage four cancer who he said recovered after taking ivermectin and the animal dewormer fenbendazole alongside other therapies. Within weeks, clips of the conversation were watched tens of millions of times across social media, reaching a public already suspicious of medical elites after the pandemic battles over off-label ivermectin use for covid.

Researchers at a major California health system later documented what happened next in the real world: prescriptions for ivermectin nearly doubled overall in the following months, and among cancer patients, prescribing of ivermectin combined with related benzimidazole drugs jumped more than two and a half times compared with the previous year. In the southern United States, where distrust of national health authorities runs deepest, those cancer prescriptions more than tripled over the same period.

What the Science Actually Shows About Ivermectin and Cancer

Long before the podcast, scientists had noticed something curious: in the lab, ivermectin does far more than kill parasites. Peer‑reviewed studies show it can slow cancer cell growth, trigger cancer cell death, and disrupt key signaling pathways such as Wnt and Akt across breast, colorectal, melanoma, and other tumor types.^[1]^[3] In mouse models, ivermectin has reduced tumor spread and sometimes boosted the effect of standard chemotherapies.^[3] That bench science explains why so many patients went looking for it.

However, oncologists emphasize that petri dishes and mice are not people. A recent medical review concluded that, while preclinical data are promising, clinical evidence in humans remains very limited and there are no large, randomized trials proving that ivermectin helps cancer patients live longer.^[1] Pediatric cancer experts likewise stress that most positive findings so far come from laboratory or animal work, not human trials.^[5] For now, there is no approval from the Food and Drug Administration for any cancer use.^[5]^[6]

Trials Begin as Patients Move Faster Than the System

Despite official caution, the federal National Cancer Institute has launched early‑phase studies testing ivermectin in combination with immunotherapy drugs like pembrolizumab for aggressive cancers such as metastatic triple‑negative breast cancer.^[4] These trials are designed to answer the question patients keep asking: can repurposed, inexpensive drugs safely enhance standard treatment or help those who have run out of options? Investigators say they want to “prove or disprove” ivermectin’s role with solid data, not social media anecdotes.^[6]

On the ground, though, doctors report that interest has already “spread like wildfire.” Some patients on chemotherapy or immunotherapy are asking to add ivermectin or fenbendazole as supplemental therapy, while a smaller but worrying number consider delaying or replacing proven treatments. A recent institutional analysis found a notable uptick in such off‑label use, often driven by online communities and podcast clips rather than physician advice. Clinicians acknowledge they are playing catch‑up as patients arrive with firm opinions shaped by their screens.

Freedom, Mistrust, and the Push for Medical Transparency

For many conservative patients, this ivermectin moment is about more than one drug. After years of seeing bureaucrats and medical associations dismiss low‑cost generics, then later quietly fund studies on the same medicines, it is no surprise that people want more control over their care. The fact that the National Cancer Institute is now formally studying ivermectin’s ability to kill cancer cells while other experts still insist “there is no evidence” it treats cancer looks, at minimum, like mixed messaging.^[3]^[6]

The responsible path forward is neither blind faith in celebrity anecdotes nor blind obedience to gatekeepers. Cancer patients deserve full, honest information: clear communication that ivermectin shows real anticancer activity in the lab, that early human trials are finally underway, and that for now it should not replace evidence‑based treatment.^[1]^[4]^[6] In a Trump‑era push for medical freedom, the federal government’s job is to cut red tape, demand transparency from the research establishment, and respect the right of informed adults—working with their doctors—to weigh risks and benefits without censorship.